Trial Profile
A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2023
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Everolimus
- Indications Carcinoma; Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 21 Dec 2021 Status changed from active, no longer recruiting to completed.
- 20 Aug 2021 Planned End Date changed from 1 Sep 2022 to 30 Oct 2021.
- 19 Apr 2021 Planned End Date changed from 1 Feb 2021 to 1 Sep 2022.